Cited by 432Drug Solubulity and Delivery SystemsAdvanced Drug Delivery SystemsDrug Transport and Resistance Mechanisms

50 years of oral lipid-based formulations: provenance, progress and future perspectives

Open access
Feeney, Orlagh M., Crum, Matthew F., McEvoy, Claire L., Trevaskis, Natalie L., Williams, Hywel D., Pouton, Colin W., Charman, William N., Bergström, Christel A.S. +1 more·2016·Advanced Drug Delivery Reviews

Abstract

Lipid based formulations (LBF) provide well proven opportunities to enhance the oral absorption of drugs and drug candidates that sit close to, or beyond, the boundaries of Lipinski's 'rule-of-five' chemical space. Advantages in permeability, efflux and presystemic metabolism are evident; however, the primary benefit is in increases in dissolution and apparent intestinal solubility for lipophilic, poorly water soluble drugs. This review firstly details the inherent advantages of LBF, their general properties and classification, and provides a brief retrospective assessment of the development of LBF over the past fifty years. More detailed analysis of the ability of LBF to promote intestinal solubilisation, supersaturation and absorption is then provided alongside review of the methods employed to assess formulation performance. Critical review of the ability of simple dispersion and more complex in vitro digestion methods to predict formulation performance subsequently reveals marked differences in the correlative ability of in vitro tests, depending on the properties of the drug involved. Notably, for highly permeable low melting drugs e.g. fenofibrate, LBF appear to provide significant benefit in all cases, and sustained ongoing solubilisation may not be required. In other cases, and particularly for higher melting point drugs such as danazol, where re-dissolution of crystalline precipitate drug is likely to be slow, correlations with ongoing solubilisation and supersaturation are more evident. In spite of their potential benefits, one limitation to broader use of LBF is low drug solubility in the excipients employed to generate formulations. Techniques to increase drug lipophilicity and lipid solubility are therefore explored, and in particular those methods that provide for temporary enhancement including lipophilic ionic liquid and prodrug technologies. The transient nature of these lipophilicity increases enhances lipid solubility and LBF viability, but precludes enduring effects on receptor promiscuity and off target toxicity. Finally, recent efforts to generate solid LBF are briefly described as a means to circumvent the need to encapsulate in soft or hard gelatin capsules, although the latter remain popular with consumers and a proven means of LBF delivery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2016.04.007

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A limited number (50%) of in vitro-in vivo correlations have been observed for lipid-based drug delivery systems based on comparing drug solubilisation in the aqueous phase of the digestion medium from the standard in vitro lipolysis model and in vivo drug absorption.

    “Despite the advances in optimising digestion conditions to more closely match the in vivo scenario, overall a limited number (50%) of in vitro -in vivo correlations (IVIVC) have been observed for LBDDS based on comparing drug solubilisation in the aqueous phase of the digestion medium from the standard in vitro lipolysis model and the in vivo drug absorption (Feeney et al., 2016).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

4 of the 289 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [52]52. R.G. Strickley, Currently Marketed Oral Lipid-Based Dosage Forms, Oral Lipid-Based Formulations, CRC Press2007, pp. 1-31.
  2. [126]126. K.A. Milton, G. Edwards, S.A. Ward, M.I. Orme, A.M. Breckenridge, The effect of food on the pharacokinetics of halofantrine in man after the administration of a single oral dose, British Journal of Clinical Pharmacology, 27 (1989) P671- P672.

Cited by

Sorted by citations

Authors
Feeney, O. M., Crum, M. F., McEvoy, C. L., Trevaskis, N. L., Williams, H. D., Pouton, C. W., Charman, W. N., Bergström, C. A. S., & Porter, C. J. H.
Affiliations
  • Monash University (AU)
  • Uppsala University (SE)
Corresponding author
Porter, Christopher J.H.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2016-06
Volume
101
Pages
167-194
ISSN
0169-409X (ISSN-L)
OpenAlex
W2339649458
Cited by
426
References
289
Citations by year
2026: 28 · 2025: 45 · 2024: 43 · 2023: 39 · 2022: 50 · 2021: 46 · 2020: 63 · 2019: 33 · 2018: 41 · 2017: 27 · 2016: 10
FWCI
3.15
Type
journal article
Language
en
Open access
Locations
  • Advanced Drug Delivery Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, other-oa)
Funders
  • Australian Research Council (CE140100036, DP110103969)
  • National Health and Medical Research Council (00010544)
  • Capsugel
  • Lipid Formulation Classification System (LFCS) Consortium
  • Pfizer and GSK
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
lipid-based formulations, oral drug absorption, poorly water-soluble drugs, supersaturation, dissolution enhancement, in vitro digestion, in vitro-in vivo correlation, ionic liquids, prodrugs, gelatin capsules, pharmaceutical excipients, drug-metabolizing enzymes, drug permeability
MeSH terms
Administration, Oral, Drug Compounding, Pharmaceutical Preparations, Emulsions, Lipids, Fenofibrate, Solubility, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review